HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Andrew N. Redington Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schulze-Neick, I. Articles by Penny, D. J. Search for Related Content PubMed PubMed Citation Articles by Schulze-Neick, I. Articles by Penny, D. J. Related Collections Cardiac - pharmacology Congenital - acyanotic Congenital - cyanotic

J Thorac Cardiovasc Surg 2002;124:435-441
© 2002 The American Association for Thoracic Surgery

Surgery for Congenital Heart Disease (CHD)

The endothelin antagonist BQ123 reduces pulmonary vascular resistance after surgical intervention for congenital heart disease

From the Cardiac Intensive Care Unit,^c Department of Vascular Biology and Pharmacology,^b and Cardiothoracic Unit,^a Great Ormond Street Hospital, London, United Kingdom.

This work was made possible by a grant from the National Heart Research Fund (No. 99-CC-10), Leeds, United Kingdom.

Received for publication May 7, 2001. Revisions requested July 6, 2001; revisions received Sept 28, 2001. Accepted for publication Oct 31, 2001. Address for reprints: D. J. Penny, MD, Cardiology Department, Royal Children's Hospital, Flemington Rd, Parkville, Victoria 3052, Australia (E-mail: pennyd{at}cryptic.rch.unimelb.edu.au).

Objective: Postoperative pulmonary hypertension in children after surgical intervention for congenital heart disease has been attributed to failure of the pulmonary endothelium to provide adequate vasodilation. Although we have shown that the impaired vasodilatory component attributable to the L-arginine-nitric oxide pathway is almost completely reversible, a nonrestorable component persists, implying an additional vasoconstrictive mechanism in postoperative pulmonary endothelial dysfunction. In this study of children after surgical intervention for congenital heart disease, we measured endothelin-1 levels and used BQ123, a selective endothelin-A receptor antagonist, together with inhaled nitric oxide to discriminate dysfunctional pulmonary endothelial vasodilation from endothelin-mediated pulmonary vasoconstriction.
Methods: All children were examined early after surgical intervention in the intensive care unit. Pulmonary vascular resistance (with respiratory mass spectrometry), as well as arterial and venous endothelin-1 levels (measured by means of a quantitative enzyme-linked immunosorbent assay), were determined in 7 children (age range, 3.3-13.7 months; median age, 6.3 months) with intracardiac shunting defects at baseline and during ventilation with a fraction of inspired oxygen of 0.65, with additional BQ123 (0.1 mg/kg infused over 20 minutes), and with inhaled nitric oxide (20 ppm).
Results: Pulmonary vascular resistance decreased from 7.7 ± 3.4 at baseline to 6.1 ± 2.8 Woods units · m^-2 (P = .022) at a fraction of inspired oxygen of 0.65 and to 4.7 ± 2.7 Woods units · m^-2 (P = .013) during BQ123 infusion. Inhaled nitric oxide had no further effect on pulmonary vascular resistance. Left atrial endothelin-1 levels (1.35-5.12 pg/mL; mean, 2.4 pg/mL) correlated significantly with the decrease in pulmonary vascular resistance in response to BQ123 infusion (r² = 0.89, P = .003).
Conclusion: Postoperative elevation of pulmonary vascular resistance in children after surgical intervention for congenital heart disease is responsive to endothelin-A blockade with BQ123. Increased levels of endothelin-1 predict the response to this therapy, which might become an important addition to the clinical armamentarium in postoperative pulmonary hypertensive disease.

This article has been cited by other articles:

				T. Kramm, B. Eberle, S. Guth, and E. Mayer Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy Eur. J. Cardiothorac. Surg., December 1, 2005; 28(6): 882 - 888. [Abstract] [Full Text] [PDF]

				C.-F. Lam, T. E. Peterson, A. J. Croatt, K. A. Nath, and Z. S. Katusic Functional adaptation and remodeling of pulmonary artery in flow-induced pulmonary hypertension Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2334 - H2341. [Abstract] [Full Text] [PDF]

				W. M. Novick, N. Sandoval, V. V. Lazorhysynets, V. Castillo, A. Baskevitch, X. Mo, R. W. Reid, B. Marinovic, and T. G. Di Sessa Flap Valve Double Patch Closure of Ventricular Septal Defects in Children With Increased Pulmonary Vascular Resistance Ann. Thorac. Surg., January 1, 2005; 79(1): 21 - 28. [Abstract] [Full Text] [PDF]

				A Rashid and D Ivy Severe paediatric pulmonary hypertension: new management strategies Arch. Dis. Child., January 1, 2005; 90(1): 92 - 98. [Abstract] [Full Text] [PDF]

				T. Nakano, H. Kado, Y. Shiokawa, K. Fukae, Y. Nishimura, K. Miyamoto, Y. Tanoue, H. Tatewaki, and N. Fusazaki The low resistance strategy for the perioperative management of the Norwood procedure Ann. Thorac. Surg., March 1, 2004; 77(3): 908 - 912. [Abstract] [Full Text] [PDF]

				J. M. Pearl, S. M. Schwartz, D. P. Nelson, C. J. Wagner, J. M. Lyons, S. M. Bauer, and J. Y. Duffy Preoperative glucocorticoids decrease pulmonary hypertension in piglets after cardiopulmonary bypass and circulatory arrest Ann. Thorac. Surg., March 1, 2004; 77(3): 994 - 1000. [Abstract] [Full Text] [PDF]